Paion Ag Aachen (PAIOF) 2.3000 $PAIOF
Sedation - Pipeline Review, H2 2015
M2 - Fri Sep 04, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wn8rs9/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Advicenne Pharma - AstraZeneca Plc - Concert Pharmaceuticals - Drawbridge Pharmaceuticals - Jiangsu Nhwa Pharma Corporation - NanoMedex Pharmaceuticals - Paion AG - The Medicines Company For more information visit http://www.researchandmarkets.com/research/wn8rs9/sedation
AZN: 32.23 (-0.16), CNCE: 20.87 (+0.62)
Timothy E. Morris Joins PAION Inc. As A Non Executive Director
PR Newswire - Fri Aug 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the appointment of Timothy E. Morris to the non executive Board of PAION, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise PAION Inc. on the financing of the company's growing U.S. activities and in preparing for the upcoming commercialisation of Remimazolam.
PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
PR Newswire - Mon Jun 08, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of the second pivotal U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.
David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc
PR Newswire - Thu May 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.
PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
PR Newswire - Tue Mar 31, 6:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy.
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Marketwire - Wed Oct 01, 7:02AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (FRANKFURT: PA8) announces today that scientific abstracts about clinical data of Remimazolam were accepted for presentation at two major US congresses. The lead investigators will present the clinical results and PAION the hypothetical product profile of its innovative, short acting anaesthetic/sedative to professionals; consisting of gastroenterologists, anaesthetists, surgeons and intensive care professionals. The booth in the commercial exhibition is part of the planned pre-marketing activities.
Sedation Therapeutics Pipeline Review 2014 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37hrjp/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Paion AG - Maruishi Pharmaceutical Co., Ltd. - NanoMedex Pharmaceuticals, Inc. - Advicenne Pharma Drug Profiles - propofol - ADV-6209 - remimazolam - MR-04A3 - ABP-700 - propofol Microemulsion - clonidine hydrochloride For more information visit http://www.researchandmarkets.com/research/37hrjp/sedation
AZN: 32.23 (-0.16)
Sedation - Pipeline Review, H2 2015
M2 - Fri Sep 04, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wn8rs9/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Advicenne Pharma - AstraZeneca Plc - Concert Pharmaceuticals - Drawbridge Pharmaceuticals - Jiangsu Nhwa Pharma Corporation - NanoMedex Pharmaceuticals - Paion AG - The Medicines Company For more information visit http://www.researchandmarkets.com/research/wn8rs9/sedation
AZN: 32.23 (-0.16), CNCE: 20.87 (+0.62)
Timothy E. Morris Joins PAION Inc. As A Non Executive Director
PR Newswire - Fri Aug 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the appointment of Timothy E. Morris to the non executive Board of PAION, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise PAION Inc. on the financing of the company's growing U.S. activities and in preparing for the upcoming commercialisation of Remimazolam.
PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
PR Newswire - Mon Jun 08, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of the second pivotal U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.
David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc
PR Newswire - Thu May 07, 7:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.
PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
PR Newswire - Tue Mar 31, 6:00AM CDT
PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy.
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Marketwire - Wed Oct 01, 7:02AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (FRANKFURT: PA8) announces today that scientific abstracts about clinical data of Remimazolam were accepted for presentation at two major US congresses. The lead investigators will present the clinical results and PAION the hypothetical product profile of its innovative, short acting anaesthetic/sedative to professionals; consisting of gastroenterologists, anaesthetists, surgeons and intensive care professionals. The booth in the commercial exhibition is part of the planned pre-marketing activities.
Sedation Therapeutics Pipeline Review 2014 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37hrjp/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Paion AG - Maruishi Pharmaceutical Co., Ltd. - NanoMedex Pharmaceuticals, Inc. - Advicenne Pharma Drug Profiles - propofol - ADV-6209 - remimazolam - MR-04A3 - ABP-700 - propofol Microemulsion - clonidine hydrochloride For more information visit http://www.researchandmarkets.com/research/37hrjp/sedation
AZN: 32.23 (-0.16)
